5 news items
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
ELTX
15 May 24
Updates AMPLIFY-201 trial: Multicenter Phase 1 trial assessing the safety, immunogenicity, and antitumor activity of ELI
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
25 Apr 24
emerge from time to time, and it is not possible for Elicio to predict all such factors, nor can Elicio assess the impact of each such factor
Elicio Therapeutics To Present Updated Clinical T Cell And Antigen Spreading Response Data From The Ongoing AMPLIFY-201 Phase 1 Study Of ELI-002 And Preclinical Data On ELI-007 And ELI-008 At The AACR Annual Meeting
ELTX
5 Apr 24
.Peripheral blood and circulating tumor DNA ("ctDNA") or serum tumor antigen were collected longitudinally to assess T cell immunogenicity
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
ELTX
5 Apr 24
tumor antigen were collected longitudinally to assess T cell immunogenicity and reductions in clinical tumor biomarkers
- Prev
- 1
- Next